DAN CUA, PH.D.
PATHWAY AREA LEADER, IL-23
Dan Cua, Ph.D. is Vice President, IL-23 Pathway Area Leader for the Immunology Therapeutic Area at Janssen Research & Development, LLC. In this role, Dan oversees the design and implementation of the scientific strategy for Discovery, Early and Late clinical Development of Janssen’s IL-23 pathway program.
Prior to Janssen, Dan served as a Senior Principal Scientist at Merck research laboratory in Palo Alto, California leading the Immunology and Immuno-Oncology Discovery groups, as well as novel research programs. Prior to Merck, Dan held roles of increasing responsibility with Schering-Plough Biopharma.
Dan is a recognized leader in the field of IL-23 biology. He has published more than 100 peer-reviewed articles, including the first publication on IL-23 regulation of immunity. His articles have been cited more 41,000 times, making him one of the most cited authors in the Immunology field. In addition, he holds 15 patents.
Dan received his Ph.D. in Molecular Microbiology and Immunology from the University of Southern California (USC) School of Medicine. He also completed two postdoctoral fellowships at the USC Department of Neurobiology within the School of Medicine and DNAX Research Institute.